Published 7 January 2026 · 6 minutes reading time
Rybelsus is oral semaglutide. It is approved for type 2 diabetes, and weight-loss use is off-label and only considered in selected cases.
Rybelsus is oral semaglutide for type 2 diabetes. Weight-loss use is off-label and needs careful medical evaluation.
Licensed Physician
Medicinskt granskad: 7 January 2026
Rybelsus is the tablet form of semaglutide. It is approved for type 2 diabetes and requires careful use when considered for weight loss.
Rybelsus is approved for diabetes management, not obesity treatment.
Dose and absorption differ from injectable GLP-1 therapy. Medical guidance is essential.
Our physicians help you develop a safe and evidence-based plan for medical weight treatment.
Part of Curevo Health
Viktenheten is part of Curevo Health, Sweden’s digital specialist care platform.
